Streetbeat News

NRBO

NeuroBo Pharmaceuticals, Inc.

https://www.neurobopharma.com

Industry

Biotechnology

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

NeuroBo Pharmaceuticals is undergoing a strategic realignment, changing its name to MetaVia Inc. and focusing on cardiometabolic diseases. The new Nasdaq ticker symbol will be MTVA, effective November 29, 2024.

Portfolio Pulse from

November 18, 2024 | 1:15 pm

NeuroBo Pharmaceuticals, a clinical-stage biotech company, will participate in investor conferences in November, including the Life Science Virtual Investor Forum on November 14.

Portfolio Pulse from

November 13, 2024 | 1:15 pm

NeuroBo Pharmaceuticals reported positive top-line data from its Phase 1 trial of DA-1726 for obesity, showing favorable safety and pharmacokinetics. The company has $21.7 million in cash, expected to fund operations into Q3 2025. Upcoming results include Phase 2a trial of DA-1241 for MASH in December 2024 and MAD Part 2 of DA-1726 in Q1 2025. A joint research agreement was entered with Dong-A ST and ImmunoForge for a long-acting formulation of DA-1726.

Portfolio Pulse from

November 07, 2024 | 1:15 pm

The article highlights significant pre-market movements in health care stocks on Wednesday. Notable gainers include Biodexa Pharmaceuticals, Carmell, Tempest Therapeutics, NovoCure, NeuroBo Pharmaceuticals, and Windtree Therapeutics. On the losing side, Novavax, Assembly Biosciences, Dogwood Therapeutics, INVO Bioscience, NewGenIvf Group, and ABVC BioPharma experienced declines.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 12:10 pm

NeuroBo Pharmaceuticals announced positive top-line results from Part 1 of its Phase 1 trial for DA-1726, a treatment for obesity. The results showed favorable safety and dose-linear pharmacokinetics. Part 2 data is expected in Q1 2025.